ACPS October 20061 Nanotechnology: Issues and Future Directions Nakissa Sadrieh Ph.D. OPS/CDER/FDA.

Slides:

Advertisements

Similar presentations

Public Health Issues Related to Mutually Conforming Labeling: CDRH Perspective Miriam C. Provost, Ph.D. Office of Device Evaluation Center for Devices.

Advertisements

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Nanotechnology: Regulatory Challenges Presented By: Phillip M. Buckler Vice President of Regulatory Affairs and Quality Kereos, Inc. St. Louis, MO Presented.

Nucleic Acid Engineering Contributors: Dr. Adolf Beyer-lein Retired Chair and Professor Emeritus Dept. of Chemistry Clemson University Dr. Wusi Maki Research.

NANOTECHNOLOGY.

Characterization of delivery systems for nanomedicine Dr. John A. Dagata.

"Informational needs and the regulatory frame for consumer applications: The EU Commission's view" Philippe Martin European Commission Directorate-General.

Nanotechnology Introduction ENGR Pre Reading Slides.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.

N ANOPARTICLES IN BIOLOGY AND MEDICINE Antti Rautiainen KE Nanopartikkelit.

Nanoparticles and their medical applications

Nanotechnology and its Application in Medicine

Chapter 4 Magnetobiology

FDA Considerations For Regulation Of Nanomaterial Containing Products

Aldrin E. Sweeney, Ph.D. Associate Professor, Science Education

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

Science and Technology of Nano Materials

1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.

Defining the right clinical problems for nanotechnology Table 2 John S. Oghalai, MD.

Regulatory Approach to Novel Nanomaterials: Unique Benefits Versus Unique Risks Russ Lebovitz, MD, PhD SUMA Partners October 6, 2006.

Corporate Office of Science and Technology © Copyright Johnson & Johnson 2004 Nanotechnology Applications in Health Care World Environment Center Nanotech.

INTRODUCTION TO RA.

Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.

REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,

1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.

Nanotechnology in Cancer Treatment

Title: Anisotropic Colloidal Magnetic Nanostructures NSF Award Numbers: # Recent years have witnessed a remarkable convergence of physical sciences,

Nanotechnology will change the nature of almost every human-made object in the next century.

1 FDA Perspective on Nanomaterial- Containing Products Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation Office of Pharmaceutical.

Center for the Environmental Implications of Nanotechology Program Solicitation NSF Preliminary Proposal Due: December 10, 2007 National Science.

Senior MESA Day.  Application of engineering technology to fields of medicine and biology.  Combines design and problem solving skills of engineering.

1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP

FDA TSE Advisory Committee Meeting October 25, 2001 Topic 2 Amino Acid Production and the Associated Theoretical Risk of BSE Transmission from their Use.

NANOTECHNOLOGY 101 A Primer Kantha Shelke, Ph.D. Natural Product Expo West March 5-8, 2009.

Nanoscale Science and Engineering. Nanoscale Science and Engineering embodies fundamental research and technology development of materials, structures,

Nanotechnology, You, and the Environment Lisa Wininger and Sara Syswerda.

Nanotechnology The concept of nanotechnology is defined as an art handling of tiny particles (1nm= m). The structures have different properties.

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

Ang Kai Yan (1) Jasmine Heng (4) Chia Zi Xuan (13) Lim Shengyang (17) Wayne Zhang (24) Done by:

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

Introduction to Nanotechnology

Applicability of Existing Regulations to the Development of a Dendrimer Nanotechnology-Based Pharmaceutical Presentation to Advisory Committee for Pharmaceutical.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Biological Computation: A Practical Examination of Nanobot Drug Delivery Connor Herring and Anthony Sciulli Biological Computation: A Practical Examination.

1 1 nanometer (nm) = 10 hydrogen atoms side-by-side Meaning of “nano”: One billionth (10x-9) Nanometer (nm) = one billionth of a.

Nanotechnology Introduction

Nanotechnology involves the creation and use of materials and devices at the level of molecules and atoms. Nanomedicine, an offshoot of nanotechnology,

Gene therapy and Viral Vectors Lecture 6. Contents Introduction to gene therapy Delivery of Therapeutic Genes Gene Therapy Targets Delivery Modes Steps.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

Nanosafety ISO TC 229 Nanotechnologies Standardization in the field of nanotechnologies that includes either or both of the following:  1. Understanding.

NANOTECHNOLOGY. NANO Prefix that means “one-billionth” Much too small with naked eye or even w/ a conventional light microscope Abbreviated “nm”

Nano means: o Prefix that means “one-billionth” o 10⁻⁹ o For example: nanometer (nm) is one-billionth of a meter o Red blood cell is about 6,000-10,000.

Nanomedicine Research at OU

Revolution of Nanotechnology Theory and Application

Overview of the emerging nanotechnology field

BTY100-Lec 2.3 Nanobiotechnology.

Muhammad Akhsin Muflikhun

Since the 1970s, the innovative development of nanoparticles is due to a combination of theory and experiments in the fields of physics chemistry materials.

Regulatory Approach to Novel Nanomaterials: Unique Benefits Versus Unique Risks Russ Lebovitz, MD, PhD SUMA Partners October 6, 2006.

From Bench to Clinical Applications: Money Talks

Quantum corral of 48 iron atoms on copper surface

Nanotechnology.

Nanotechnology Prepared by: ASHWINI GHORPADE.

Resources for Teaching Nanoscience Across the Geoscience Curriculum

Nano Technology Dr. Raouf Mahmood. Nano Technology Dr. Raouf Mahmood.

Nanotechnology: Issues and Future Directions

Presentation transcript:

ACPS October Nanotechnology: Issues and Future Directions Nakissa Sadrieh Ph.D. OPS/CDER/FDA

ACPS October Outline Introduction (Nakissa Sadrieh, FDA) Applicability of existing regulations to the development of a dendrimer nanotechnology-based pharmaceutical (Jeremy Paull, Starpharma) Nanotechnology in emerging medical and consumer products-Opportunities and risks (Russel Lebovitz, Suma Partners) Questions to the ACPS (Nakissa Sadrieh, FDA)

ACPS October Why is there interest in nanotechnology? At the nanoscale, the physical, chemical, and biological properties of materials differ in fundamental and valuable ways from the properties of individual atoms and molecules or bulk matter. Nanotechnology R&D is directed toward understanding and creating improved materials and systems that exploit these new properties.

ACPS October Nanotechnology is the understanding and control of matter at dimensions of roughly 1 to 100 nanometers, where unique phenomena enable novel applications. Encompassing nanoscale science, engineering and technology, nanotechnology involves imaging, measuring, modeling, and manipulating matter at this length scale. NNI Definition

ACPS October Applications of Nanoparticles to Drug Discovery and Biology Fluorescent biological markers Detection of proteins Probing of DNA structures Separation and purification of biological molecules and cells MRI contrast enhancement Tumor destruction via heating Tissue engineering Drug and gene delivery (Nanomarkets, March 2005)

ACPS October Trends in Development of Nanoparticles in Medicine Currently, nanoparticle applications in medicine are geared towards drug discovery and drug delivery. In the future, the goal is to make the nanoparticles multifunctional and controllable by external signals or local environments.

ACPS October Possible Opportunities for Nanotechnology in Drug Delivery Enhanced drug properties such as: Solubility Rate of dissolution Oral bioavailability Targeting ability Enhanced dosing requirements: Lower dosed administered Better side effect profile More convenient dosage forms

ACPS October FDA-Regulated Products Expected to be Impacted by Nanotechnology Drugs (novel NMEs or delivery systems) Medical devices Biotechnology products Tissue engineering products Vaccines Cosmetics Combination products

ACPS October Examples of Nanotechnology Combination Product Multi-component system that may consist of: Carrier/delivery system (drug or device) Therapeutic agent (drug or biologic) Imaging agent Targeting agent Implantable microchip-based delivery systems that deliver different drugs under controlled conditions. Injectable delivery systems (transdermal microneedles). (Nanomarkets, March 2005)

ACPS October Are nanomaterials new to FDA? Drugs: Imaging agents (Gadolinium MRI contrast agents, iron oxide contrast agent). Reformulated drugs using nanocrystal technology to enhance bioavailability properties of previously approved drugs (immunosuppressant, antiemitic). Liposomal products Nanoparticle-based formulation of previously approved anti-tumor agent

ACPS October Other “nano-scale” products on the market Devices Silver nanoparticles (anti-bacterial wound dressing) Engineered Calcium Phosphate (duplicates microstructure, composition and performance of human bone) Nanoparticle dental restorative Cosmetics (“nanosomes”) Sunscreens (TiO2 and ZnO)

ACPS October FDA Activities in Nanotechnology Nanotechnology interest group within the Office of the Commissioner. Working groups within individual Centers. Internal nanotechnology task force established by the acting Commissioner. Public meeting in October 2006 to understand developments in nanotechnology. MOU between FDA, NCI and NIST. Research

ACPS October Current approach Specific consideration may need to be given to nanoparticle-containing products, in the areas of: Characterization Safety

ACPS October Current thinking within CDER nanotechnology working group CDER/FDA’s current requirements for safety testing of products is very rigorous. However if research identifies toxicological risks that are unique to nanomaterials, additional testing requirements may become necessary. At this time, there are no testing requirements that are specific to nanotechnology products.

ACPS October What about a Nanotechnology Product Guidance Document? Guidances are built on precedence from review and on extensive literature data. Because nanotechnology is an evolving field and we are still learning, CDER is not anticipating any new preclinical or CMC guidance documents regarding nanomaterials in the near future.

ACPS October Review Process for Nanotechnology Drugs The effectiveness of the agency’s regulatory approach to meet unique challenges that may be presented by the use of nanotechnology materials in FDA-regulated products is currently being evaluated. However, in the meantime, and based on the available information, the review process for products containing nanomaterials is likely to essentially remain the same as that used for products that do not contain nanomaterials.